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ABSTRACT 
Objectives: To classify community pharmacies (CPs) in Riyadh, Saudi Arabia, in terms of the quality of medicines sold 
by them, using the lot quality assurance sampling (LQAS) technique with a predefined threshold. Methods: Riyadh 
CPs were divided into 2 categories (“lots” for the purpose of LQAS), i.e., chain and independent CPs. Upper and lower 
rate thresholds for CPs that sell low-quality medicines were predefined as 20% and 5%, respectively. Consumer and 
provider risks were predefined as 0.05 and 0.10, respectively. The calculated number of randomly selected CPs required 
in each lot was 36; then, sale of low-quality medicines in >3 CPs implies a prevalence of >20% of such CPs according 
to LQAS. A randomly selected brand of amoxicillin (selected as a quality indicator of medicines because it is both 
widely counterfeited and heat-sensitive) was purchased from each pharmacy by a “mystery shopper”, checked for au-
thenticity, and analyzed for drug content and content uniformity using a validated HPLC method. Results: Substandard 
amoxicillin was purchased in 9 pharmacies (4 chains and 5 independent). Both lots were thus rejected as unacceptable, 
which may indicate that consumers in Riyadh are at risk of purchasing substandard medicines at CPs. Conclusions: The 
quality of medicines sold in CPs in Riyadh did not meet our acceptability criterion, and appropriate intervention by de-
cision makers is recommended. LQAS proved to be a practical, economical, and statistically valid sampling method for 
surveying the quality of medicines. It should enable decision makers to allocate resources for improvement more effi-
ciently. 
 
Keywords: Amoxicillin; Antibiotic; Quality of Medicines; Lot Quality Assurance Sampling; Saudi Arabia; Community 
Pharmacy 
1. Introduction 
Low-quality medicines are a global issue because of their 
increasing prevalence and the potentially serious conse- 
quences of their use [1,2]. Although developing countries 
are the principal targets of counterfeiters, developed 
countries also face many of the same risks [3,4]. Es- 
sential medicines (e.g., antimicrobials) are the most 
frequently targeted products in developing countries [5- 
8]. 
Low-quality medicines may be either counterfeit or 
substandard [9,10]. Regardless of the product quality and 
amount of active ingredients, counterfeit medicines are 
defined as those made by unauthorized manufacturers 
with the intention of cheating, and this definition covers 
both the medicine and its packaging. Substandard me- 
dicines are produced by legitimate manufacturers, but do 
not fulfill the manufacturing quality standards or do not 
contain the correct amount of active ingredient(s). In 
addition, medicines that have passed their expiration date 
or that have deteriorated due to improper distribution 
and/or storage conditions (i.e., degraded medicines) may 
also be considered substandard, even if they were ori- 
ginally genuine and of good quality [11]. 
Studies with sound and replicable methodology on the *Corresponding author. 
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quality of medicines in developing countries are very 
limited. Convenience sampling is widely used for this 
purpose, even though bias is clearly introduced because 
usually only accessible pharmacies or outlets are selected. 
Formal random sampling generally requires a larger 
sample, longer surveying time, and more resources. For 
these reasons, Lot Quality Assurance Sampling (LQAS) 
has been proposed as an economical technique to survey 
the quality of medicines sold in community pharmacies 
(CPs) [11]. LQAS was developed in the 1920s to assess 
the quality of industrial products by inspecting random 
samples [12]. It was later adapted for a variety of health 
surveys and settings, though not surveys of the quality of 
medicines in the supply chain [13,14]. Because LQAS 
uses a relatively small sample, it cannot determine the 
prevalence (rate) of outlets that sell low-quality medi- 
cines, but rather provides a way to classify the rate as 
either acceptable or unacceptable in terms of predeter- 
mined criteria. Thus, it may be helpful to enable decision 
makers to properly allocate and distribute resources 
among various supervisory areas, and also provides an 
indication as to whether or not larger-scale, randomized 
surveys are required.  
In Saudi Arabia self-medication is common and var- 
ious prescription medicines, including antibiotics, can be 
purchased from CPs without a prescription, despite the 
government’s regulations [15,16]. Recently, the Saudi 
Food and Drug Authority (SFDA) was es- tablished as an 
independent corporate body that reports directly to the 
President of the Council of Ministers. It is responsible for 
ensuring the safety of food and drugs for human and 
veterinary use and the safety of biological and chemical 
substances and medical devices [17]. 
Among antibiotics, amoxicillin is widely used in de- 
veloping countries, and it is included in the list of es- 
sential drugs issued by the World Health Organization 
(WHO) [18]. It is also considered an essential drug in 
primary health care in Saudi Arabia [19]. It is also among 
the most widely counterfeited medicines in developing 
countries [3,5]. Substandard amoxicillin has already been 
identified in Saudi Arabia in one study [8]. Furthermore, 
amoxicillin products, including suspensions and capsules, 
are sensitive to heat and may degrade easily at tem- 
peratures above 30˚C [20]. Therefore, we focused on 
amoxicillin as an indicator of the quality of medicines in 
the supply chain in Saudi Arabia, where high tempera- 
tures are common. 
We aimed to explore the quality of amoxicillin cap- 
sules and tablets sold in CPs in Riyadh, Saudi Arabia, as 
an indicator of the quality of medicines sold in these 
pharmacies, using the LQAS technique. Based on a 
review of the literature on the quality of amoxicillin in 
developing countries [3,5,8,21,22], we formulated as our 
null hypothesis that more than 20% of the CPs in Riyadh, 
in either the chain or independent category, sell low- 
quality amoxicillin. 
2. Methods 
This study was approved by the Ethical Committee of 
Kanazawa University and by the SFDA. Samples in the 
original packaging were collected between September 21 
and October 3, 2010, individually placed in sealed bags, 
packed in thermally insulated plastic cool boxes, and 
shipped to Kanazawa University, Japan, via a secure 
courier after obtaining the necessary clearance docu- 
ments. The analysis was performed in the Department of 
Drug Management and Policy at Kanazawa University 
between May 25, 2011 and February 7, 2012 (before the 
expiration dates of all samples). The cool boxes were 
kept in the laboratory at a controlled room temperature of 
22˚C until analysis. 
Because 2 levels of sampling (pharmacies and amo- 
xicillin brands) were included in this study, the term 
“sample” is used to indicate amoxicillin samples and the 
term “subject” for the pharmacies selected for the study. 
The term “target pharmacy” refers to a pharmacy that sold 
low-quality amoxicillin. In general, the survey methodo- 
logy and reporting were consistent with the Medicine 
Quality Assessment Reporting Guidelines (MEDQUARG) 
proposed by Newton et al. [11]. 
2.1. Selection of Pharmacies 
A list of registered CPs in Riyadh was obtained from the 
Saudi Ministry of Health (MOH) in July 2010 (1367 
pharmacies). The pharmacies were divided into 2 
categories, i.e., chain and independent (869 and 498 
pharmacies, respectively). An independent pharmacy was 
defined as one belonging to a group of ≤3 pharmacies, 
whereas a chain pharmacy was defined as one belonging 
to a group of >3 pharmacies [23]. Each category was 
designated as a “lot”for the purpose of LQAS. 
The required number of pharmacies in each lot and the 
decision rule were calculated according to the LQAS 
technique. The binomial LQAS formula (Figure 1(a)) is 
preferred if the population size is either unknown or very 
large [24]. In the present study, we used the hypergeo- 
metric LQAS model (Figure 1(b)) because each subject 
pharmacy was included only once and because the 
population size of pharmacies in each lot was known and 
relatively small [25,26]. These characteristics allow the 
actual errors to be calculated more accurately. In this 
model, the gamma function was used for the calculation 
of factorials of fractions (Figure 1(c)). A calculator that 
uses this calculation method is available online [27]. 
Studies from developing countries have reported a  
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variety of rates of sale of counterfeit and substandard 
antimicrobials ranging from 2.8% to > 50%, with the 
majority of the rates lying within the range of 30% - 40% 
[3]. In addition, various levels of amoxicillin content, 
ranging from 0% to 85% of the labeled amount, have 
been reported [3,5,8,21,22]. Based on the above reports, 
we adopted the following upper and lower prevalence 
thresholds in this study: a lot with a rate of target 
pharmacies >20% was classified as a high-prevalence lot 
(so that the null hypothesis was not rejected for this lot), 
whereas a lot with a rate of target pharmacies ≤5% was 
classified as a low-prevalence lot. This criterion for the 
low-prevalence lot is considered acceptable, because it is 
preferable to devote limited resources to improve CPs in 
the high-prevalence lot. The consumer risk (alpha error 
based on the null hypothesis) and the provider risk (beta 
error) were predetermined to be ≤0.05 and ≤0.10, res- 
pectively. 
target pharmacies in either lot exceeds the decision value, 
the lot is classified as a high-prevalence lot and the null 
hypothesis is not rejected. Otherwise, the lot will be 
classified as a low-prevalence lot. The LQAS decision 
rule only classifies the rate as either >the predefined 
upper threshold or ≤the predefined lower threshold. It is 
not sensitive to rates between these thresholds. It is worth 
mentioning that formal random sampling would have 
 
(a)                       (b)                       (c) 
 The minimum number of subject pharmacies that 
produced the lowest combination of cumulative errors at 
both thresholds was 36 pharmacies in each lot, with 3 as 
the value for the decision rule (Table 1). If the number of 
Figure 1. The LQAS Equations. (a) The binomial formula; 
(b) the hypergeometric formula; (c) the factorial of a frac-
tion. 
 
Table 1. Part of the calculation process for deciding the required number of subject pharmacies and the decision rule. 
x Sensitivity  (at upper threshold of 0.20) 
Cumulative alpha error 
(consumer risk) 
Cumulative specificity  
(at lower threshold of 0.05) 
Beta error  
(provider risk) Total error 
For chain pharmacies (N = 869) when n = 36  
0 0.9997 0.0003 0.1517 0.8483 0.8486 
1 0.9972 0.0028 0.4519 0.5481 0.5509 
2 0.9855 0.0145 0.7336 0.2664 0.2809 
3 0.9512 0.0488 0.9006 0.0994 0.1482 
4 0.8783 0.1217 0.9708 0.0292 0.1509 
5 0.7591 0.2409 0.9931 0.0069 0.2478 
6 0.6027 0.3973 0.9987 0.0013 0.3986 
For independent pharmacies (N = 498) when n = 36 
0 0.9998 0.0002 0.1471 0.8529 0.8531 
1 0.9975 0.0025 0.4481 0.5519 0.5544 
2 0.9866 0.0134 0.7348 0.2652 0.2786 
3 0.9538 0.0462 0.9039 0.0961 0.1423 
4 0.8823 0.1177 0.9732 0.0268 0.1445 
5 0.7633 0.2367 0.9941 0.0059 0.2426 
6 0.6054 0.3946 0.999 0.001 0.3956 
The first 7 rows of probability combinations are shown. x = decision rule, N = population size, n = required number of subject pharmacies, sensitivity = 1 − 
cumulative alpha error, Beta error = 1 − cumulative specificity. Minimum accepted errors (and their sum) occur when x = 3 in the round of n when n = 36 for 
each lot (shaded areas of the table). This indicates that the smallest required number of subject pharmacies is 36. If the calculation continues, other good com-
binations will be obtained. However, this would require additional pharmacies. At n = 36, the finding of ≤3 target pharmacies indicates that their rate in the 
corresponding lot is ≤5%. However, this rate is acceptable according to the predefined thresholds in this study. The finding of >3 target pharmacies means that 
eir rate is >20%. Because this rate is unacceptable, the corresponding lot (i.e., category of pharmacy) is rejected. th  
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required a 4- to 5-fold larger number of pharmacies in 
each category, and therefore the resources required 
would have been 4- to 5-fold greater. This represents a 
significant advantage for LQAS. 
A list of pharmacies in each category was created and 
each pharmacy was coded. The lists were scrambled, and 
45 pharmacies (36 + 9) were randomly selected from 
each list with MS Excel 2010 (Microsoft Co., USA). The 
additional 9 pharmacies represented a reserve for an 
estimated dropout rate of 25%. Dropout could be for any 
of the following reasons: a) the pharmacy was closed on 
the second visit; b) the pharmacy was out of business; c) 
the pharmacy did not have the required quantity of 
amoxicillin dosage units; or d) the pharmacy refused to 
sell amoxicillin without a prescription. 
In theory, LQAS sampling can be terminated if the 
decision rule is exceeded at an early stage of the survey, 
thereby minimizing cost and time requirements, though 
this was not the case in the present study. 
2.2. Amoxicillin Sampling 
The “mystery shopper” technique with the same scenario 
was used in purchasing samples [28,29]. The sampler 
asked the seller to show him all brands of amoxicillin 
capsules and tablets available in 4 - 5 packs (80 dosage 
units) because one of the sampler’s friends wanted the 
medicine. The sampler also told the seller that he would 
call his friend to tell him about the available brands and 
strengths to allow the friend to select the product to be 
purchased. The brands were numbered in a list reflecting 
the order in which the seller presented them, excluding 
any clavulanate-containing products. Each strength of a 
given brand was treated as a separate brand. A mobile 
telephone was used to rapidly generate a random number 
between 1 and the highest number on the list with Excel 
Mobile. This procedure was conducted while the sampler 
appeared to be making the call. In this way, one brand 
was randomly purchased from each randomly selected 
pharmacy. If the packs were from more than one batch of 
the same brand, they were considered as different sam- 
ples purchased from the same pharmacy. Packs from the 
same batch of the same brand purchased from different 
pharmacies were also considered as different samples. 
After sampling, the sampling form was immediately 
completed outside the pharmacy (Table 2). Samples 
were immediately placed in a plastic cool box and the car 
air-conditioner was operating effectively during all sam- 
pling trips. Amoxicillin brands were coded with the 
letters A-P. 
2.3. Authenticity Investigations 
Dosage units, strips, boxes, and package inserts of all 
samples were visually inspected. Parts of all those items  
Table 2. Sampling information. 
Pharmacy code and type Dosage form 
Sample code Strength 
Sampling date Package size 
Package condition and type Registration number in  Saudi Arabia 
Trade name Batch number 
Manufacturer’s name Manufacture date 
Manufacturer’s country Expiration date 
Distributor in Saudi Arabia Price 
 
were sent to the corresponding manufacturers for authen- 
ticity confirmation. The SFDA was contacted to verify 
the registration status of the products. 
2.4. Analysis and Materials 
The samples were analyzed in the order of their expira- 
tion dates. The content uniformity test was performed 
according to the 34th edition of the United States 
Pharmacopeia (USP), but using a shorter HPLC column 
(15 cm instead of 25 cm) [30,31]. The use of the shorter 
column would not have affected the results, since the 
method was validated. For every sample the amoxicillin 
content, which should range from 90.0% - 120.0% for 
capsules and 90.0% - 110.0% for tablets, according to the 
USP, was calculated by averaging the content of the 
dosage units analyzed in the content uniformity test. 
All chemicals used were of analytical grade. Acetoni- 
trile, potassium dihydrogen phosphate, and potassium 
hydroxide were purchased from Nakalai Tesque (Kyoto, 
Japan). Standard amoxicillin, conforming to the USP 
Reference Standard (USPRS), was obtained from the 
Department of Medical Sciences, Bureau of Drugs and 
Narcotics, Ministry of Public Health, Thailand. Standard 
cefadroxil, from Sigma (St Louis, MO, USA), was used 
as the internal standard. 
The HPLC system consisted of the following com- 
ponents from JASCO (Tokyo, Japan): a pump (PU-2080 
Plus), a UV detector (UV-2075 Plus) set at 230 nm, a 
column thermostat (CO-1560), a degasser (DG-980-50), 
a system controller (LC-Net II/ADC), and an auto- 
sampler (AS-950). The system was equipped with a 4.6 × 
150 mm Shim-pack CLC-ODS (M) column from Shi- 
madzu (Kyoto, Japan), filled with 70% methanol. The 
system was linked with a computer running ChromNav 
software from JASCO (Tokyo, Japan) to analyze the 
results and to plot curves and peaks. 
A calibration curve was produced daily, using 3 
concentrations of standard amoxicillin (0.05, 0.10, and 
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0.2 mg/mL) prepared from a fresh stock solution of 1 
mg/mL amoxicillin (on anhydrous base). The linearity of 
the standard amoxicillin/diluent solution was maintained 
between 0.025 and 0.5 mg/mL and the analytical range 
was 0.05 - 0.4 mg/mL. A stock solution of standard ce- 
fadroxil (0.2 mg/mL, on anhydrous base) was also fre- 
shly prepared daily and was added to all sample and 
calibration solutions to obtain a final concentration of 0.1 
mg/mL in each solution. 
The final sample and calibration solutions were fil- 
tered through 0.2 µm Minisart RC 4 syringe filters from 
Sartorius Stedim (Dublin, Ireland). All solutions were 
used within 6 hours of preparation and analyzed in 
triplicate. 
For method validation, intra- and inter-day precision 
tests were performed using standard amoxicillin, and the 
accuracy was evaluated by applying the standard- 
addition (spiking) recovery technique, using aliquots of 
pre-analyzed samples. All values of standard deviation, 
relative standard deviation, and relative error for both 
precision and accuracy were <2%, based on a 95% 
confidence interval. These values were considered satis- 
factory. 
3. Results 
Eighty-three samples were collected from the 72 phar- 
macies. Of these samples, 41 were collected from chain 
pharmacies and 42 from independent pharmacies (Table 
3). Six samples (7%) were tablets and the others were 
capsules. Twenty-eight samples (35%) were locally ma- 
nufactured, 47 (57%) were imported from other Arab 
countries, and 7 (8%) were imported from Europe. The 
samples included 16 brands produced by 10 manu- 
facturers. These samples represented all the manufac- 
turers registered by the SFDA at the time of sampling. 
The dropout rate was 7 and 6 for chain and independent 
pharmacies, respectively. Dropouts occurred for the 
reasons mentioned above, and no major differences in 
reasons for dropping out were found between the in- 
dependent and chain categories. 
The authenticity of the samples was confirmed by all 
manufacturers, and the registration status of each product 
and manufacturer was confirmed by the SFDA. 
A total of 9 samples (11%), all of which were capsules, 
failed the content uniformity test. The failed samples 
were purchased from 9 pharmacies (4 chain and 5 
independent) that belonged to different chains or owners 
and included 5 brands from 4 manufacturers (Figure 2). 
The content of 6 of the failed samples was below 90%. 
The lowest content was 80.7% and the content of the 
approved samples ranged from 90.6% to 104.2% (Figure 
3). Interestingly, certain batches of certain brands passed 
the content and/or content uniformity tests in some  
 
Figure 2. Distribution of failed samples. 
 





code From 36 chain 
pharmacies 








Ac 4 4 8 3 
Bc 4 3 7 5 
Cd 2 0 2 2 
Dd 3 4 7 6 
Ed 3 7 10 6 
Fe 1 0 1 1 
Ge 2 0 2 2 
Hd 0 1 1 1 
Id 6 1 7 5 
Jc 1 5 6 4 
Kd 3 2 5 3 
Le 0 4 4 3 
Md 4 6 10 10 
Nc 2 0 2 2 
Oc 5 1 6 2 
Pd 1 4 5 3 
Total 41 42 83 57 
aA sample is a batch purchased from a single pharmacy. If the same batch is 
purchased at another pharmacy, it is considered as a different sample. Dif-
ferent batches of the same brand purchased from the same pharmacy are also 
considered as different samples. bThe number of batches of the correspond-
ing brand purchased from all pharmacies without repetition. cManufactured 
in Saudi Arabia. dImported from other Arab countries. eImported from Eu-
rope. 
 
pharmacies, but failed in others (Table 4). 
The number of target pharmacies in each lot was 
greater than the decision value. For this reason, we failed  
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Figure 3. Content distribution of all samples. 
 
Table 4. Batches that passed in some pharmacies but failed in others. 
Samples of the same batch 
Brand 
No. Status 




Average content (%) Pharmacy type 
1 Failed 15.66 92.36 Independent 
B 
2 Passed 07.35 94.74 Independent 
1 Failed 19.92 86.81 Independent 
D 
2 Passed 14.20 91.11 Independent 
1 Failed 27.06 84.43 Independent 
2 Passed 05.57 95.96 Chain 
3 Passed 08.46 95.38 Chain 
O 
4 Passed 13.21 93.57 Chain 
1 Failed 15.08 90.66 Independent 
2 Failed 17.24 91.89 Independent P 
3 Passed 08.26 95.41 Independent 
aAcceptance value must be ≤15%. 
 
samples in the present work was very low (8%). All 
tablet forms passed the quality tests in our study, but 
again the significance of this result is uncertain because 
of the small percentage of tablets (7%). According to the 
SFDA (e-mail communication, Jul 6, 2010), the sales of 
tablet forms and European brands in Saudi Arabia during 
the second quarter of 2009 amounted to 3.96% and 
4.32% of the total sales of amoxicillin (capsules and 
tablets), respectively. 
to reject the null hypothesis, and both lots were classified 
as high-prevalence lots. Thus, our results indicate that 
more than 20% of the pharmacies in each lot sell low- 
quality amoxicillin, an outcome suggestive of a signi- 
ficant problem with important public health implications. 
4. Discussion 
Substandard samples amounted to 11% of the total 
samples, indicating a rather high prevalence of sub- 
standard amoxicillin products in CPs in Riyadh. This is 
consistent with the findings of Kyriacos et al., although 
the sample size for amoxicillin products purchased in 
Saudi Arabia was not specified in that study [8]. Like 
them, we found that all European samples passed the 
quality tests, although the percentage of European 
The finding that some samples from the same batch 
passed the tests in certain pharmacies, but failed in others, 
suggests the occurrence of degradation of the failed 
samples, which may originally have been of good quality. 
Degradation may have occurred due to poor storage and/ 
or distribution conditions. The samples were collected 
during a very hot season, when the outside temperature 
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in Riyadh during daytime reached approximately 45˚C. 
Poor temperature control in the distributors’ facilities, 
such as warehouses and delivery vehicles, could have 
been resulted in degradation of amoxicillin. Although the 
air conditioning in the vast majority of the visited phar- 
macies was satisfactory during sampling, the possibility 
that the air conditioners had failed or were not in use in 
certain pharmacies at certain times cannot be excluded. 
However, we cannot exclude poor quality-control prac- 
tices during the manufacturing process. This possibility 
is supported by the fact that powder in some capsules of 
failed samples from one manufacturer was in the form of 
a hard mass, possibly formed when the samples dried out 
after having absorbed moisture. Thus, poor packaging 
may have been a contributory factor. 
The average content of the active ingredient in failed 
samples was greater than 80%. This value contrasts with 
the low value found by Kyriacos et al. (59%) [8]. 
However, our results seem consistent with the findings of 
a study conducted in Indonesia, where 20% of the 
amoxicillin tablets analyzed contained an amount of 
active ingredient that was only slightly below the accep- 
table range according to the British Pharmacopeia (BP) 
[22]. Note that in our study two more samples would 
have failed the content test (1 sample from each lot), 
based on the content range of 92.5% - 110.0% specified 
in BP 2012 [32]. The intake of poor-quality antibiotics 
may lead to therapeutic failure and the emergence of 
bacterial resistance [3]. 
The number of target pharmacies exceeded the 
decision value in both lots (i.e., chain and independent 
categories). This finding suggests that intervention 
strategies should target both types of CPs. Further, the 
unacceptable rate of CPs that sell low-quality medicines 
in Riyadh, a capital city where inspection and monitoring 
are expected to be relatively strict, suggests that the 
situation may be even worse in other cities or more 
remote areas of the country. It might be advisable for the 
SFDA to perform routine monitoring of wholesalers and 
pharmacy storage facilities, distribution facilities, and 
environmental conditions inside pharmacies (e.g., tem- 
perature, humidity, and exposure to sunlight). In addition, 
distributors, pharmacy owners, and pharmacists should 
be educated about the possible consequences of failing to 
adhere to appropriate distribution and storage conditions 
for the provision of medicines. 
LQAS proved to be a practical method for surveying 
the quality of medicines sold in CPs, using rather small 
numbers of pharmacies for sampling, and it may be a 
suitable approach for future monitoring by the SFDA or 
other investigators in Saudi Arabia, as well as other 
countries. The same methodology can be used for follow- 
up to monitor changes that may have occurred following 
interventions. However, the medicine selected as an 
indicator of the quality of medicines may need to be 
changed according to the nature of the study or the 
geographical area surveyed. In our study, amoxicillin 
was selected because it is widely used, widely counter- 
feited, and heat-labile (Riyadh is very hot during sum- 
mer), and also because substandard amoxicillin was 
reported in Saudi Arabia in one study. 
5. Limitations 
The following limitations may have influenced the re- 
sults of this study. First, only capsule and tablet dosage 
forms of amoxicillin were sampled. Therefore, the find- 
ings cannot necessarily be extended to other dosage 
forms or other medicines.  
Second, it was not possible to collect samples of a 
single batch from each pharmacy because asking the 
seller about batches would have revealed that the phar- 
macy was under investigation. 
Third, samples were analyzed by the chief investigator, 
who was not blinded as to the samples being analyzed, 
but was blinded as to the pharmacy from which the 
sample(s) were obtained. Unintentional expectation bias 
might have been introduced because the chief investi- 
gator is a Saudi clinical pharmacist. However, this factor 
is unlikely to have affected the results of the study, 
because there were several samples that failed from 
certain pharmacies but passed from others, and because 
the samples were repeatedly measured with a validated 
method.  
Fourth, only content and content uniformity tests were 
conducted. Therefore, “quality” in this study refers only 
to the acceptable amount and uniformity of the active 
ingredient in terms of the ranges specified by the USP. 
Finally, because some samples passed the content test 
while other samples from the same batch but purchased 
from different pharmacies failed it, we assumed that the 
failed samples had been degraded. However, we did not 
analyze them for degradation products. There are several 
methods that can differentiate between degraded and 
originally substandard amoxicillin [33,34]. These methods 
may be used in future studies. 
6. Conclusions 
Although this study has several limitations, the results 
indicate that there are deficiencies in quality control 
within the supply chain (including customs clearance of 
imported medicines) and/or in storage facilities in Riyadh, 
either at the level of wholesalers or pharmacies, in 
addition to possible manufacturing or packaging defects 
in some brands of amoxicillin.  
LQAS with a mystery shopper provided a readily 
reproducible and statistically valid sampling method for 
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investigating the quality of medicines sold at CPs. 
Finally, we recommend further studies to investigate 
the adherence of CPs, and other facilities in the supply 
chain in Riyadh, to optimal conditions for keeping and 
selling medicines. Larger-scale randomized surveys 
would be helpful to further delineate the scale of the 
quality-control problem in CPs. 
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